Wednesday, July 8, 2026

Patent intelligence · US

US 10835604

Biomaterials for combined radiotherapy and immunotherapy of cancer

granted A61KA61K39/00A61K41/0038A61K47/6923
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 14
Applicant portfolio 595
Patent details — US 10835604
Jurisdiction
US
Status
granted
Grant date
Nov 17, 2020
Expiration
Nov 12, 2040
Claims
20
CPC classes
A61K, A61K39/00, A61K41/0038, A61K47/6923
View on Google Patents ↗

Quick answer

US 10835604 (Biomaterials for combined radiotherapy and immunotherapy of cancer) is held by Northwestern University. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K39/00, A61K41/0038, A61K47/6923, A61K47/6929, A61K49/0428

More from Northwestern University

Related pharmaceutical patents in our USPTO index.

  1. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Expires Sep 18, 2045

    granted
  2. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University · Expires Sep 11, 2045

    granted
  3. US 12414981

    JNK inhibitors for use in treating and preventing neurodegenerative disorders

    Northwestern University · Expires Sep 11, 2045

    granted
  4. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Northwestern University · Expires Sep 11, 2045

    granted
  5. US 12415995

    Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

    Northwestern University · Expires Sep 11, 2045

    granted
  6. US 12409205

    Nanomolecules for the treatment of inflammatory bowel diseases

    Northwestern University · Expires Sep 4, 2045

    granted
  7. US 12410474

    Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient

    Northwestern University · Expires Sep 4, 2045

    granted
  8. US 12404533

    Bioconjugate vaccines' synthesis in prokaryotic cell lysates

    Northwestern University · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 10835604?

US 10835604 (Biomaterials for combined radiotherapy and immunotherapy of cancer) is held by Northwestern University. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10835604?

Northwestern University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 595 pharmaceutical patents for this assignee.

When does US 10835604 expire?

Our index shows an expiration date of Nov 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.